Glioblastoma is the most common and aggressive brain tumor in adults. Despite surgery, radiation, and chemotherapy, survival rates remain low, which emphasizes the urgent need for improved therapies. Current preclinical models use untreated tumors, which do not reflect the clinical scenario where patients already receive initial treatments. This review examines the effects of current treatments on the properties of recurrent tumors and evaluates preclinical models that incorporate these standard treatments to better mimic real patient conditions. Improving these models could help to identify more effective treatments, potentially leading to better outcomes for glioblastoma patients.
BHL Holiday Party
The BHL Annual Holiday Party brought the team together to mark the end of the year. We shared food, spent time together, and played a white elephant gift exchange. It was a nice opportunity to connect outside the lab!
December 20, 2025
